title: Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
abstract: 1. The chemically novel acetohydroxamic acids, BW A4C, BW A137C and BW A797C, are potent inhibitors of the synthesis of leukotriene B4 (LTB4) from arachidonic acid by human leucocyte homogenates: the concentrations required for 50% inhibition (IC50) were 0.1 microM, 0.8 microM and 0.5 microM respectively. Inhibition was less at higher concentrations of arachidonic acid. 2. These compounds also inhibited the synthesis of [14C]-5-HETE from [14C]-arachidonic acid and the calcium-dependent synthesis of LTB4 from 5-HPETE. This, therefore, suggests that they inhibit 5-lipoxygenase and LTA4 synthase. 3. Concentrations of acetohydroxamic acids required to inhibit metabolism of arachidonic acid by cyclo-oxygenase, 12-lipoxygenase and 15-lipoxygenase were 10 to 100 times higher than those required to inhibit 5-lipoxygenase. 4. The compounds were potent inhibitors of LTB4 synthesis induced by the ionophore, A23187, in human intact leucocytes. This inhibition was reversed by washing the cells. They were also potent, selective inhibitors of LTB4 synthesis induced by A23187 in whole rat blood: binding to rat plasma proteins did not greatly reduce the effectiveness of the compounds. 5. The effects of the acetohydroxamic acids, administered either intravenously or orally to rats, on the synthesis of LTB4, and thromboxane B2 (TXB2) in A23187-stimulated blood ex vivo was studied. The three compounds caused dose-dependent inhibition of the synthesis of LTB4 but not TXB2. Inhibition of LTB4 synthesis persisted for up to 6 h after a single oral dose of 50 mg kg-1. 6. The plasma concentrations of unchanged compound determined by h.p.l.c. correlated with the inhibition of LTB4 synthesis ex vivo.
authors.affiliation: Department of Medicinal Chemistry, Wellcome Research Laboratories, Beckenham, Kent.
authors.forename: J E
authors.initials: JE
authors.lastname: Tateson
authors.forename: R W
authors.initials: RW
authors.lastname: Randall
authors.forename: C H
authors.initials: CH
authors.lastname: Reynolds
authors.forename: W P
authors.initials: WP
authors.lastname: Jackson
authors.forename: P
authors.initials: P
authors.lastname: Bhattacherjee
authors.forename: J A
authors.initials: JA
authors.lastname: Salmon
authors.forename: L G
authors.initials: LG
authors.lastname: Garland
mesh_terms: D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000097:blood; D001091:Arachidonate Lipoxygenases / Q000037:antagonists & inhibitors*; D001249:Asthma / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002352:Carrier Proteins / Q000097:blood; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D006877:Hydroxamic Acids / Q000097:blood / Q000494:pharmacology*; D066298:In Vitro Techniques; D007962:Leukocytes / Q000187:drug effects / Q000378:metabolism; D007975:Leukotriene B4 / Q000096:biosynthesis; D016859:Lipoxygenase Inhibitors; D008297:Male; D051381:Rats; D013929:Thromboxane B2 / Q000096:biosynthesis
chemical_list: D002352:Carrier Proteins; D006877:Hydroxamic Acids; D016859:Lipoxygenase Inhibitors; D007975:Leukotriene B4; C006358:acetohydroxamic acid; D013929:Thromboxane B2; D001091:Arachidonate Lipoxygenases; D001094:Arachidonate 5-Lipoxygenase